01273 704473

info@novuscomms.com

01273 704473

info@novuscomms.com

#HVO hVIVO PLC – Appointment of Non-Executive Director December 18, 2025 – Posted in: hVIVO (HVO)

hVIVO plc (AIM: HVO), a full-service early phase Contract Research Organisation (CRO) and the world leader in human challenge clinical trials, announces the appointment of Richard Cotton as Independent Non-Executive Director, effective today. Richard will also serve as Chair of the Audit Committee and as a member of the Remuneration and Nominations Committees.   Richard brings extensive Board-level and financial expertise, including experience serving as Chair, Audit Chair and Senior Independent Director, as well as holding advisory…

Continue reading

#HVO hVIVO PLC – Appointment of Independent Non-Executive Director May 29, 2025 – Posted in: Blog, hVIVO (HVO)

hVIVO plc (AIM: HVO), a full-service Contract Research Organisation (CRO) and the world leader in human challenge clinical trials, announces that further to its announcement on 12 May 2025, the Company has appointed Tracey James as Independent Non-Executive Director from 1 June 2025. Tracey will be Chair of the Audit Committee, and a member of the Remuneration and Nominations Committees. Tracey is a Chartered Accountant with 26 years’ experience working at Grant Thornton UK LLP…

Continue reading

#POLB Poolbeg Pharma PLC – Board Role Change and Launch of EIP February 15, 2024 – Posted in: Blog, Poolbeg Pharma (POLB)

15 February 2024 – Poolbeg Pharma (AIM: POLB, OTCQB: POLBF, “Poolbeg” or the “Company”), a biopharmaceutical company focussed on the development and commercialisation of innovative medicines targeting diseases with a high unmet medical need, announces a change of Board role and the Remuneration Committee’s approval of the adoption of an Employee Performance Incentive Plan (“EIP”) for a number of the key senior management, to align medium and long term objectives with those of shareholders and to encourage…

Continue reading

#POLB Poolbeg Pharma PLC – Directorate Change November 30, 2023 – Posted in: Blog, Poolbeg Pharma (POLB)

30 November 2023 – Poolbeg Pharma (AIM: POLB, OTCQB: POLBF, ‘Poolbeg’ or the ‘Company’), a biopharmaceutical company focussed on the development and commercialisation of innovative medicines targeting diseases with a high unmet medical need, announces a change to its Board of Directors. Patrick Ashe, Independent Non-Executive Director, will step down from the Board at the end of November. Eddie Gibson, Non-Executive Director will replace Patrick as Chair of the Audit & Risk Committee and Prof Brendan Buckley, Non-Executive Director…

Continue reading